$VCEL

Halpin Michael sold $468K of VCEL

Halpin Michael (Chief Operating Officer) sold 10,000 shares of Vericel Corp (VCEL) at $46.84 ($0.47M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Halpin Michael
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCEL
Neutral
high confidence
Mentioned
$VCEL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCELNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and 10b5-1 status by the COO, which can marginally influence sentiment but does not change company fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total insider holdings beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Vericel Corp (VCEL).

Company-level read

Ticker impact

$VCELNeutralHigh confidence
Context

Vericel COO Michael Halpin sold 10,000 shares in an open-market transaction at $46.84 on 2026-08-03, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, and the article provides no new company fundamentals, guidance, or regulatory/clinical catalysts.

Market effects

Minimal; insider sale does not disclose sector-wide regulatory, clinical, or reimbursement changes.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Vericel Corp

    Company whose insider transaction is disclosed on SEC Form 4.

  • Michael Halpin

    Chief Operating Officer who sold 10,000 shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, reducing interpretive weight of the sale.

Related articles

$VCELMedAI 8/10

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.

$VCELHigh

Vericel Corp (VCEL): Results of Operations and Financial Condition

Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Sh